Telomir Pharmaceuticals announces preclinical study of Telomir-Zn in age-related macular degeneration model
Telomir Pharmaceuticals announced on September 17, 2026 the publication of a peer-reviewed preclinical study in International Journal of Molecular Sciences showing Telomir-Zn improved visual function and retinal structure in a model of age-related macular degeneration. The filing contains no financial results, and the study is preclinical, so it does not change the company's oncology clinical development focus.
Key points
- Study published in International Journal of Molecular Sciences, 2026, 27(18), 8265, with Telomir-Zn dosed orally for 14 days in the model
- Study reported significant improvement in visual performance and restoration of thickness across multiple retinal layers
- Clinical development remains focused on a Phase 1/2 trial in advanced or metastatic triple-negative breast cancer under an FDA-cleared IND
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.